Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.

Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer. Oncol Lett. 2018 Oct;16(4):4984-4996 Authors: Wu N, Zhang J, Zhao J, Mu K, Zhang J, Jin Z, Yu J, Liu J Abstract As a clinically heterogeneous subtype of breast cancer, triple-negative breast cancer (TNBC) is associated with a poor clinical outcome and a high relapse rate. Conventional chemotherapy and radiotherapy are effective treatments for patients with TNBC. However, the prognosis of TNBC remains unsatisfactory. Therefore, a large volume of research has explored the molecular markers and oncogenic signaling pathways associated with TNBC, including the cell cycle, DNA damage response and androgen receptor (AR) signaling pathways, to identify more efficient targeted therapies. However, whether these predicted pathways are effective targets has yet to be confirmed. In the present review, potentially carcinogenic signaling pathways in TNBCs from previous reports were considered, and ultimately five tumorigenic signaling pathways were selected, specifically receptor tyrosine kinases and downstream signaling pathways, the epithelial-to-mesenchymal transition and associated pathways, the immunoregulatory tumor microenvironment, DNA damage repair pathways, and AR and coordinating pathways. The conclusions of the preclinical and clinical trials of each pathway were then consolidated. Although a number of signaling pathways in TNBC have been consi...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research